查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924709

猴痘抗原检测试剂市场按产品类型、技术、检测类型、检体类型和最终用户划分－2026-2032年全球预测

Monkeypox Antigen Test Reagent Market by Product Type, Technology, Test Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年猴痘抗原检测试剂市值为 1.4514 亿美元，预计到 2026 年将成长至 1.6627 亿美元，到 2032 年预计将达到 3.2135 亿美元，复合年增长率为 12.02%。

关键市场统计数据
基准年 2025 1.4514亿美元
预计年份：2026年 1.6627亿美元
预测年份 2032 3.2135亿美元
复合年增长率 (%) 12.02%

本文简要概述了目前抗原试剂的现状，并探讨了影响猴痘诊断策略的技术、监管和操作因素。

猴痘已成为新的诊断重点领域，加速了抗原检测方法和整体诊断流程的创新。本执行摘要介绍了目前抗原检测试剂的现状，重点阐述了影响采购和实施决策的技术差异、最终用户需求和操作限制。文中也提供了相关背景信息，帮助读者理解不同医疗机构中的检测形式、设备和检体处理方法如何与监管途径和临床效用相互关联。

诊断技术研发、监管方法和供应链预期的重大系统性变革正在重新定义抗原试剂的创新和应用。

技术进步、终端用户需求的变化以及供应链重组正在推动多重变革，重塑抗原试剂生态系统。在许多情况下，照护现场能力已从“理想”变为“必需”，促使製造商优先考虑侧向流动检测形式和简化的工作流程，以减少对集中式检查室基础设施的依赖。同时，生物感测器灵敏度的提高和微流体整合技术的进步，使得更复杂的检测模式成为可能，这些模式与传统的酶联免疫吸附试验 (ELISA) 相辅相成，促进了兼顾速度和分析严谨性的混合工作流程的形成。

不断变化的关税制度和贸易政策趋势正在推动供应链重组、在地化和策略采购，以确保试剂供应稳定并维持利润率。

影响跨境贸易和进口关税的政策行动对试剂供应、价格波动和生产策略有重大影响。关税上调会直接增加进口零件和成品的到岸成本，挤压利润空间，并可能促使企业采取即时采购模式，从而减少库存缓衝。为此，许多生产商和采购商正在加快采购多元化的步伐，评估区域生产能力，并重新谈判供应合同，以减少对单一供应商的依赖。随着时间的推移，这些调整往往会将采购重心转移到拥有国内或邻近采购能力的供应商。同时，依赖全球供应商网路的企业则被要求加强合约保障措施和紧急时应对计画。

将产品架构、检测技术、最终用户画像、测试方法和检体类型与策略发展和采购选择联繫起来的详细細項分析

深度細項分析揭示了技术选择、临床工作流程和采购行为之间的交集，从而影响试剂部署和产品开发优先顺序。相关人员应根据产品类型评估分析仪器和检测套组之间的差异。分析仪器包括侧向流读取仪和微孔盘读数仪，它们具备定量和高通量检测能力；而检测套组则包括生物感测器试剂盒、ELISA试剂盒和侧向层析试剂盒，这些试剂盒针对不同的操作环境而设计。这些差异会影响买方对通量、连接性和检验数据的要求，并决定製造商为将其检测方法整合到临床路径中而寻求的伙伴关係类型。

从区域视角比较美洲、欧洲、中东和非洲以及亚太地区的监管多样性、采用驱动因素和供应链现状

区域趋势将对美洲、欧洲、中东和非洲以及亚太地区的采纳路径、监管参与和供应链配置产生重大影响。在美洲，医疗保健系统尤其重视快速采纳并与现有临床工作流程整合，从而推动了对就地检验和仪器化侧向层析解决方案的需求，这些解决方案能够提供及时的临床资讯。该地区的支付和采购机制倾向于选择可扩展的解决方案，这些解决方案需展现出明确的临床效用和与实验室资讯系统的兼容性。

製造商、创新者和通路合作伙伴之间的竞争行为和策略联盟决定了产品的覆盖范围、检验成功率和供应可靠性。

抗原试剂领域的竞争格局呈现出多元化的特点，既有成熟的诊断公司，也有灵活的利基创新者、契约製造和能够实现快速检测部署的平台提供者。主要企业强调整合价值提案，将试剂产品组合、仪器平台和数位化结果管理结合，透过捆绑式产品和服务协议锁定机构客户。小规模的公司则往往透过技术新颖性脱颖而出，例如增强型生物感测器化学和微流体集成，并致力于开发快速诊断能够带来可衡量的临床和营运效益的特定应用场景。

产业领导者应采取哪些切实可行的策略步骤和营运投资，以提高抗原试剂的稳定性、加速应用推广并增强临床效用？

产业领导者应优先采取一系列重点突出、切实可行的措施，以增强韧性并加速技术应用。首先，投资于模组化平台设计，使相同的底层化学原理能够应用于侧向流动、生物感测器和微流体多种技术，从而加快产品上市速度，并为不同的检测方法提供灵活的生产方式。其次，扩大与代表性终端使用者（诊所、医院检查室、独立诊断中心和研究机构）的检验伙伴关係，收集各种检体类型（包括血浆、唾液、血清、拭子和全血）的性能数据，确保使用说明能反映实际工作流程。

一项透明的、三角验证的研究途径，结合了相关人员访谈、检查室证据审查和政策分析，对诊断性能和供应链的说法检验。

本分析整合了结构化调查方法的研究成果，该方法结合了关键相关人员的对话、检查室检验审查和系统的二手研究。关键投入包括对诊断开发人员、临床检查室主任、采购负责人和监管专家的深入访谈，以了解不同终端使用者环境下的决策标准、检验方法和采购限制。检查室检验审查侧重于同行评审出版物、监管申报文件和製造商技术文件中的测试性能特征、与检体类型的兼容性以及设备整合要求。

整合诊断优先事项、技术权衡和战略要务，这将决定试剂的成功应用和长期应用。

总之，猴痘抗原试剂的现状正处于技术创新、不断变化的监管环境和不断变化的供应链动态的交汇点。诊断决策者必须权衡快速分散检测的需求与分析稳健性和互通性的要求。技术方法已分化为两种：一种是优先考虑可及性的快速侧向层析法，另一种是支援高灵敏度和高通量的仪器化检测方法。这两种方法的重要性将取决于临床应用场景和医疗环境。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 猴痘抗原检测试剂市场（依产品类型划分）

  • 分析设备
    • 侧向流读取仪
    • 微孔盘读数仪
  • 检测套组
    • 生物感测器套件
    • ELISA试剂盒
    • 侧向流动试剂盒

9. 依技术分類的猴痘抗原检测试剂市场

  • 生物感测器
  • 酵素免疫分析法
    • 比色法
    • 萤光检测法
  • 横向流动化验
    • 胶体金侧向流动
    • 萤光侧向流动
  • 微流体技术

第十章 猴痘抗原检测试剂市场（依检测类型划分）

  • 检查室检测
  • 快速检测
    • 就地检验
    • 自我检查

第十一章 依检体类型分類的猴痘抗原检测试剂市场

  • 电浆
  • 唾液
  • 血清
  • 拭子
  • 全血

第十二章：猴痘抗原检测试剂市场（依最终用户划分）

  • 诊所
  • 诊断检查室
  • 医院
    • 公立医院
    • 私立医院
  • 研究所

第十三章 猴痘抗原检测试剂市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 猴痘抗原检测试剂市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国猴痘抗原检测试剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国猴痘抗原检测试剂市场

第十七章：中国猴痘抗原检测试剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Autobio Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • BTNX, Inc.
  • CerTest Biotec SL
  • Era Biology Co., Ltd.
  • Getein Biotech, Inc.
  • Hangzhou Clongene Biotech Co., Ltd.
  • Hotgen Biotech Co., Ltd.
  • InTec Products, Inc.
  • JOYSBIO Biotechnology Co., Ltd.
  • Nanjing Poclight Biotechnology Co., Ltd.
  • Roche Diagnostics GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Virax Biolabs Ltd.
Product Code: MRR-7A380DA7C440

The Monkeypox Antigen Test Reagent Market was valued at USD 145.14 million in 2025 and is projected to grow to USD 166.27 million in 2026, with a CAGR of 12.02%, reaching USD 321.35 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 145.14 million
Estimated Year [2026] USD 166.27 million
Forecast Year [2032] USD 321.35 million
CAGR (%) 12.02%

A concise orientation to the antigen reagent landscape that contextualizes technical, regulatory, and operational drivers influencing diagnostic strategies for monkeypox

The emergence of monkeypox as an area of renewed diagnostic focus has accelerated innovation across antigen detection modalities and diagnostic workflows. This executive summary introduces the contemporary landscape for antigen test reagents, framing the discussion around technological differentiation, end-user requirements, and operational constraints that shape procurement and deployment decisions. It situates the reader to understand how assay formats, instrumentation, and sample handling interrelate with regulatory pathways and clinical utility in varied care settings.

The narrative that follows synthesizes observable dynamics across product types and testing technologies, examines the implications of evolving trade and tariff environments, and highlights the strategic pressures affecting manufacturers, distributors, and service providers. Throughout, the emphasis is on translating complex technical and policy developments into clear implications for stakeholders involved in diagnostics design, supply chain management, and public health preparedness. By foregrounding practical considerations such as turnaround time, ease of use, and compatibility with existing laboratory infrastructure, this introduction sets the stage for a deeper analysis of shifts, segmentation nuances, regional characteristics, and tactical recommendations that can inform near-term decisions and longer-term capability building.

Critical systemic changes in diagnostic development, regulatory approaches, and supply chain expectations that are redefining antigen reagent innovation and adoption

Several transformative shifts are reshaping the antigen reagent ecosystem, driven by technological advances, shifting end-user expectations, and supply chain realignment. Point-of-care readiness has moved from desirable to essential in many settings, prompting manufacturers to prioritize lateral flow formats and simplified workflows that reduce dependence on centralized laboratory infrastructure. Concurrently, improvements in biosensor sensitivity and microfluidic integration are enabling more nuanced detection paradigms that can complement traditional enzyme-linked approaches, fostering hybrid workflows that balance speed and analytical rigor.

Regulatory environments are also evolving to accommodate accelerated review pathways for high-priority diagnostics, which in turn influences development timelines and go-to-market strategies. At the same time, procurement and reimbursement frameworks are increasingly calibrated to emphasize clinical utility and cost-effectiveness, encouraging vendors to demonstrate clear patient outcome benefits. Finally, data integration expectations are rising: stakeholders now demand interoperable reporting, digital result capture, and analytics-ready outputs that support surveillance and provider decision-making. Together, these shifts create both opportunity and pressure, compelling organizations to invest in flexible platforms, robust validation, and partnerships that bridge technology, clinical adoption, and supply resilience.

How evolving tariff regimes and trade policy dynamics are prompting supply chain realignment, localization, and strategic sourcing to preserve reagent access and margin stability

Policy measures affecting cross-border trade and import duties have material implications for reagent availability, pricing dynamics, and manufacturing strategies. When tariffs increase, they directly raise landed costs for imported components and finished products, which can compress margins and incentivize just-in-time procurement that reduces inventory buffers. In response, many producers and purchasers accelerate efforts to diversify sourcing, evaluate regional manufacturing capacity, and renegotiate supply agreements to mitigate single-source dependencies. Over time, such adjustments typically shift procurement toward suppliers with domestic or nearshore capabilities when available, while firms reliant on global supplier networks must strengthen contractual protections and contingency planning.

Tariff-driven cost pressures also influence investment decisions related to automation, localization of production lines, and partnerships with contract manufacturers. Diagnostic developers may prioritize modular platforms that can be produced in multiple geographies to reduce exposure to trade volatility. In parallel, distributors and health systems reassess SKU rationalization and inventory strategies to preserve access without incurring unsustainable expense. Importantly, compliance obligations and customs complexity introduce administrative overhead that favors suppliers with established global logistics expertise. In short, tariff dynamics act as a catalyst for supply chain realignment, supplier consolidation in some segments, and accelerated emphasis on manufacturing agility and contractual risk management.

In-depth segmentation analysis connecting product architectures, detection technologies, end-user profiles, test modalities, and specimen types to strategic development and procurement choices

Deep segmentation reveals where technology choices, clinical workflows, and purchasing behaviors intersect to shape reagent deployment and product development priorities. Based on product type, stakeholders must weigh differences between analytical instruments and test kits: analytical instruments encompass lateral flow readers and microplate readers that add quantitative or higher-throughput capability, while test kits include biosensor kits, ELISA kits, and lateral flow kits designed for varying operational contexts. These distinctions influence buyer requirements for throughput, connectivity, and validation data, and they determine the types of partnerships that manufacturers pursue to embed their assays into clinical pathways.

Based on technology, developers navigate trade-offs among biosensors, enzyme-linked immunosorbent assays, lateral flow assays, and microfluidics. Enzyme-linked formats are subdivided into colorimetric and fluorometric readouts that differ in sensitivity and instrumentation needs, whereas lateral flow assays split into colloidal gold and fluorescence lateral flow formats, each with distinct detection thresholds and manufacturing considerations. Based on end user, the landscape spans clinics, diagnostic laboratories, hospitals, and research institutes; clinics include community and outpatient clinics, diagnostic laboratories encompass hospital and independent labs, and hospitals may be government or private. These end-user distinctions drive purchasing cycles, validation expectations, and required service models. Based on test type, the spectrum ranges from laboratory tests to rapid tests; laboratory tests further separate into automated and manual assays, while rapid tests distinguish point-of-care tests from self-tests, reflecting divergent regulatory and usability requirements. Finally, based on sample type, performance and logistics are shaped by the use of plasma, saliva, serum, swab, and whole blood, each imposing specific collection, transport, and storage conditions that influence kit formulation and instructions for use.

Comparative regional outlook highlighting regulatory diversity, adoption drivers, and supply chain realities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence adoption pathways, regulatory interactions, and supply chain configurations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, health systems exhibit a pronounced focus on rapid deployment and integration with existing clinical workflows, driving demand for point-of-care and instrumented lateral flow solutions that provide timely clinical information. Payment and procurement mechanisms in this region often favor scalable solutions that demonstrate clear clinical utility and compatibility with laboratory information systems.

Europe, the Middle East & Africa present a heterogeneous regulatory and operational environment where harmonization and cross-border procurement patterns vary considerably. In parts of Europe, centralized regulatory scrutiny emphasizes analytical performance and post-market surveillance, while resource variability across the Middle East & Africa shapes demand for low-cost, robust formats that tolerate supply chain variability. In the Asia-Pacific region, significant manufacturing capacity coexists with diverse adoption curves; some markets prioritize high-throughput laboratory solutions and automation, while others accelerate point-of-care and self-test availability to expand access. Across all regions, interoperability, regulatory alignment, and supply reliability remain central determinants of successful product introduction and sustained uptake.

Competitive behaviors and strategic alignments among manufacturers, innovators, and channel partners that determine product reach, validation success, and supply reliability

Competitive dynamics in the antigen reagent arena are characterized by a mix of established diagnostics firms, agile niche innovators, contract manufacturers, and platform providers that enable rapid assay deployment. Leading organizations emphasize integrated value propositions that combine reagent portfolios with instrument platforms and digital result management, seeking to lock in institutional customers through bundled offerings and service contracts. Smaller companies often differentiate through technological novelty-such as enhanced biosensor chemistries or microfluidic integration-and by pursuing targeted use cases where rapid diagnostics can demonstrate measurable clinical or operational benefit.

Strategic behaviors observed include licensing arrangements that accelerate market entry, co-development partnerships with clinical laboratories to ensure real-world validation, and manufacturing scale-up agreements to manage capacity constraints. Additionally, companies increasingly pursue regulatory harmonization strategies, compiling evidence packages designed to align with multiple jurisdictions' requirements. Distribution partnerships and channel diversification are also vital, as access to healthcare networks and procurement entities determines uptake. Taken together, these behaviors indicate an industry balancing the need for rigorous validation with the urgency of deployment, where collaboration across clinical, commercial, and manufacturing domains is a prerequisite for success.

Practical strategic moves and operational investments that industry leaders should implement to improve resilience, expedite adoption, and strengthen clinical utility of antigen reagents

Industry leaders should prioritize a set of focused, actionable initiatives to strengthen resilience and accelerate adoption. First, invest in modular platform designs that enable the same underlying chemistry to be configured across lateral flow, biosensor, and microfluidic formats, thereby reducing time-to-market for variant assays and enabling flexible manufacturing. Second, expand validation partnerships with representative end users-clinics, hospital laboratories, independent diagnostic centers, and research institutes-to collect diverse performance data across sample types such as plasma, saliva, serum, swab, and whole blood, ensuring that instructions for use reflect real-world workflows.

Third, fortify supply chains by qualifying alternate suppliers, exploring regional manufacturing or contract manufacturing partnerships, and incorporating tariff exposure into procurement contracts to dampen cost volatility. Fourth, enhance product appeal through integration with digital reporting and result capture, improving interoperability with laboratory information systems and public health surveillance platforms. Fifth, engage early with regulatory authorities to clarify evidence expectations for different test types, whether automated laboratory assays or point-of-care devices, and to expedite pathways for emergency or prioritized review when appropriate. Finally, align commercial strategies to emphasize bundled service offerings, training, and technical support that reduce barriers to adoption in resource-constrained settings and foster long-term customer relationships.

A transparent, triangulated research approach combining stakeholder interviews, laboratory evidence review, and policy analysis to validate diagnostic performance and supply chain assertions

This analysis synthesizes insights derived from a structured research methodology combining primary stakeholder engagement, laboratory validation review, and systematic secondary research. Primary inputs included in-depth interviews with diagnostic developers, clinical laboratory directors, procurement officers, and regulatory specialists to capture decision-making criteria, validation practices, and procurement constraints across diverse end-user settings. Laboratory validation review focused on assay performance characteristics, sample type compatibility, and instrument integration requirements drawn from peer-reviewed publications, regulatory filings, and manufacturer technical dossiers.

Secondary research involved cross-referencing publicly available regulatory guidance, trade policy publications, and industry white papers to contextualize tariff and supply chain dynamics. Evidence was triangulated through multiple sources to reduce bias and to validate technical claims. Wherever feasible, claims about assay performance were corroborated against independent evaluations and regulatory summaries rather than vendor promotional materials. The methodology recognizes limitations related to rapidly evolving policy environments and the proprietary nature of some commercial agreements, and therefore emphasizes transparent sourcing and conservative interpretation of commercially sensitive assertions.

Synthesis of diagnostic priorities, technological trade-offs, and strategic imperatives that will determine successful reagent deployment and long-term adoption

In conclusion, the antigen reagent landscape for monkeypox represents a confluence of technological innovation, regulatory evolution, and shifting supply chain dynamics. Diagnostic decision-makers must balance the need for rapid, decentralized testing with requirements for analytical robustness and interoperability. Technological pathways diverge between rapid lateral flow approaches that prioritize accessibility and instrumented assays that support higher sensitivity and throughput, and both paths will remain relevant depending on the clinical use case and care setting.

Strategic resilience will come from flexible platform design, diversified manufacturing footprints, and deeper engagement with end users to ensure that assay formats meet operational needs across clinics, hospitals, diagnostic laboratories, and research institutes. Policy environments, including tariff dynamics and regulatory adjustments, further underscore the importance of agility in supplier selection and contractual risk management. Ultimately, organizations that integrate rigorous validation, supply chain foresight, and clear value propositions tied to clinical outcomes will be best positioned to support effective diagnostic responses and sustained adoption in varied healthcare contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Monkeypox Antigen Test Reagent Market, by Product Type

  • 8.1. Analytical Instrument
    • 8.1.1. Lateral Flow Reader
    • 8.1.2. Microplate Reader
  • 8.2. Test Kit
    • 8.2.1. Biosensor Kit
    • 8.2.2. Elisa Kit
    • 8.2.3. Lateral Flow Kit

9. Monkeypox Antigen Test Reagent Market, by Technology

  • 9.1. Biosensor
  • 9.2. Enzyme Linked Immunosorbent Assay
    • 9.2.1. Colorimetric
    • 9.2.2. Fluorometric
  • 9.3. Lateral Flow Assay
    • 9.3.1. Colloidal Gold Lateral Flow
    • 9.3.2. Fluorescence Lateral Flow
  • 9.4. Microfluidics

10. Monkeypox Antigen Test Reagent Market, by Test Type

  • 10.1. Laboratory Test
  • 10.2. Rapid Test
    • 10.2.1. Point Of Care Test
    • 10.2.2. Self Test

11. Monkeypox Antigen Test Reagent Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Saliva
  • 11.3. Serum
  • 11.4. Swab
  • 11.5. Whole Blood

12. Monkeypox Antigen Test Reagent Market, by End User

  • 12.1. Clinic
  • 12.2. Diagnostic Laboratory
  • 12.3. Hospital
    • 12.3.1. Government Hospital
    • 12.3.2. Private Hospital
  • 12.4. Research Institute

13. Monkeypox Antigen Test Reagent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Monkeypox Antigen Test Reagent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Monkeypox Antigen Test Reagent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Monkeypox Antigen Test Reagent Market

17. China Monkeypox Antigen Test Reagent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Autobio Diagnostics Co., Ltd.
  • 18.6. Becton, Dickinson and Company
  • 18.7. BTNX, Inc.
  • 18.8. CerTest Biotec S.L.
  • 18.9. Era Biology Co., Ltd.
  • 18.10. Getein Biotech, Inc.
  • 18.11. Hangzhou Clongene Biotech Co., Ltd.
  • 18.12. Hotgen Biotech Co., Ltd.
  • 18.13. InTec Products, Inc.
  • 18.14. JOYSBIO Biotechnology Co., Ltd.
  • 18.15. Nanjing Poclight Biotechnology Co., Ltd.
  • 18.16. Roche Diagnostics GmbH
  • 18.17. Siemens Healthineers AG
  • 18.18. Sino Biological Inc.
  • 18.19. Virax Biolabs Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW READER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW READER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW READER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROPLATE READER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROPLATE READER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROPLATE READER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ELISA KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ELISA KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ELISA KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUOROMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUOROMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUORESCENCE LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUORESCENCE LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUORESCENCE LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LABORATORY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LABORATORY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LABORATORY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY POINT OF CARE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY POINT OF CARE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY POINT OF CARE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SELF TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SELF TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SELF TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GOVERNMENT HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GOVERNMENT HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GOVERNMENT HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 222. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 258. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 270. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)